Birmex will focus on the supply of inputs in the period 2025-2030

Ángeles Cruz Martínez

La Jornada Newspaper
Wednesday, January 7, 2026, p. 15

Biological and Reactive Laboratories of Mexico (Birmex) will focus on correcting technological obsolescence and ensuring the supply of supplies in the health sector, since it maintains the responsibility of purchasing medicines and other supplies, as well as distribution. Although it plans to resume the production of vaccines and medicines, the 2025-2030 program indicates that “within the framework of republican austerity”, it will carry out the diagnosis and determine priorities regarding the state of the infrastructure, equipment and devices it has.

Among the activities contained in five objectives is to promote linkages, technological transfer, knowledge and innovation between institutions and sectors, for modernization and new production lines.

Birmex’s institutional program was published yesterday in the Official Gazette of the Federation and recognizes that shortages of essential medicines and treatments have been caused by deficiencies in the purchasing and distribution processes.

This is a task assigned to the parastatal since December 2023, however there have been persistent failures in the supply chain, the document acknowledges.

It points out that the cause of the shortage of supplies in public health institutions is also due to operational and logistical deficiencies, structural limitations in the production capacity, acquisition, storage and distribution of strategic medical supplies.

The program indicates that in the following years, consolidated purchases of medicines and health supplies will be optimized with efficiency, effectiveness and transparency. All this with the assurance that the State will obtain the best conditions in price, quality, financing and opportunity.

It also warns that the State’s productive and logistical infrastructure has not been used optimally. Birmex’s has been underutilized for several years when it concentrated on the purchase of vaccines and biologicals, thereby “leaving aside the reactivation and modernization of its production plants.” Among the tasks to resume its production capacity, Birmex plans to propose research, development and manufacturing projects for biologicals and other products.

Another line of action of Birmex is to “favor the training of human resources for the development of national scientific talent.”